>
Switch to:

Allergy Therapeutics Long-Term Capital Lease Obligation

: $9.8 Mil (As of Jun. 2021)
View and export this data going back to 2004. Start your Free Trial

Allergy Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2021 was $9.8 Mil.

Allergy Therapeutics's quarterly Long-Term Capital Lease Obligation increased from Jun. 2020 ($8.7 Mil) to Dec. 2020 ($9.1 Mil) and increased from Dec. 2020 ($9.1 Mil) to Jun. 2021 ($9.8 Mil).

Allergy Therapeutics's annual Long-Term Capital Lease Obligation increased from Jun. 2019 ($0.0 Mil) to Jun. 2020 ($8.7 Mil) and increased from Jun. 2020 ($8.7 Mil) to Jun. 2021 ($9.8 Mil).


Allergy Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Allergy Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Long-Term Capital Lease Obligation
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 8.75 9.77

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Long-Term Capital Lease Obligation Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 9.88 8.75 9.10 9.77

Allergy Therapeutics  (OTCPK:AGYTF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Allergy Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)